Borgil Holding has announced that its Board of Directors has approved the appointment of Dr. Shamsheer Vayalil as Chief Executive Officer, in addition to his current role as Founder and Chairman, pending necessary approvals from shareholders and regulatory authorities.
The Board’s decision reflects its assessment that Borgil Holding has reached a stage of development and expansion that allows for the alignment of strategic leadership with operational oversight. This aims to support clinical excellence, promote systematic growth, and create long-term value for the group.
Commenting on his appointment, Dr. Shamsheer Vayalil stated, “Borgil boasts an exceptional portfolio of healthcare assets that provides a strong and scalable foundation for growth and value enhancement. With careful capital management and a clear strategic vision, I will focus on elevating performance across the entire portfolio, fostering sustainable growth, and building long-term value that benefits all stakeholders.”
The Board has also approved the necessary procedures for the formalization of this appointment, including obtaining shareholder approval through a general assembly meeting per existing regulations. Additionally, the Board decided that this leadership transition will be accompanied by strengthened independent oversight mechanisms, particularly through the governance of the Board and its committees, ensuring the highest levels of accountability and protection of shareholder interests.
The Board has confirmed the termination of the roles of John Sunil as CEO and Ambassador Ahmed as Co-CEO, expressing appreciation for their leadership and contributions to the development of Borgil Holding’s performance.
Borgil Holding will continue to implement its strategic approach aimed at enhancing its leadership in complex and specialized care, reinforcing Abu Dhabi’s position as a regional hub for medical referrals. The group also plans systematic expansions in both the UAE and Saudi Arabia, while establishing low-capital operational partnerships. There is a continued commitment to optimizing existing assets, supported by ongoing investments in clinical capabilities, digital healthcare acceleration, AI-enhanced solutions, and scientific research, all while maintaining a strong focus on outcome quality and sustainable growth.
Furthermore, the Board has approved the budget for the fiscal year 2026, marking the highest annual budget ever approved by the group.
Additional details regarding the shareholder general meeting and related approvals will be announced timely by the stakeholders in accordance with applicable regulations.